Crossmark

A small-molecule PI3Kα activator for cardioprotection and neuroregeneration

Crossref DOI link: https://doi.org/10.1038/s41586-023-05972-2

Published Online: 2023-05-24

Published Print: 2023-06-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gong, Grace Q. https://orcid.org/0000-0002-7609-0466
Bilanges, Benoit https://orcid.org/0000-0003-4400-3716
Allsop, Ben

Masson, Glenn R. https://orcid.org/0000-0002-1386-4719
Roberton, Victoria https://orcid.org/0000-0002-0404-6984
Askwith, Trevor

Oxenford, Sally

Madsen, Ralitsa R.

Conduit, Sarah E. https://orcid.org/0000-0002-5075-8851
Bellini, Dom

Fitzek, Martina

Collier, Matt

Najam, Osman

He, Zhenhe

Wahab, Ben

McLaughlin, Stephen H. https://orcid.org/0000-0001-9135-6253
Chan, A. W. Edith

Feierberg, Isabella

Madin, Andrew

Morelli, Daniele

Bhamra, Amandeep

Vinciauskaite, Vanesa https://orcid.org/0000-0001-9226-1731
Anderson, Karen E. https://orcid.org/0000-0002-7394-6660
Surinova, Silvia https://orcid.org/0000-0003-0442-9595
Pinotsis, Nikos https://orcid.org/0000-0002-5096-257X
Lopez-Guadamillas, Elena

Wilcox, Matthew

Hooper, Alice

Patel, Chandni

Whitehead, Maria A.

Bunney, Tom D. https://orcid.org/0000-0002-0281-8813
Stephens, Len R. https://orcid.org/0000-0002-2771-3487
Hawkins, Phillip T. https://orcid.org/0000-0002-6979-0464
Katan, Matilda https://orcid.org/0000-0001-9992-8375
Yellon, Derek M.

Davidson, Sean M. https://orcid.org/0000-0001-5182-4980
Smith, David M. https://orcid.org/0000-0001-6831-280X
Phillips, James B. https://orcid.org/0000-0001-8117-3074
Angell, Richard

Williams, Roger L. https://orcid.org/0000-0001-7754-4207
Vanhaesebroeck, Bart https://orcid.org/0000-0002-7074-3673
License Information

Text and Data Mining valid from 2023-05-24

Version of Record valid from 2023-05-24
More Information

Article History

Received: 17 September 2021

Accepted: 17 March 2023

First Online: 24 May 2023

Competing interests

: B.V. is a consultant for iOnctura, Venthera, Pharming and Olema Pharmaceuticals, and has received speaker fees from Gilead. M.F., M.C., I.F., A.M. and D.M.S. are or were employees and shareholders in AstraZeneca at the time of the work done. J.B.P. is co-Founder and Chief Scientific Officer of the UCL spin-out company Glialign. A patent application WO2023041905, with relevance to this work has been filed by UCL Business Ltd, covering ‘Aminopyridines as activators of PI 3 kinase’ that lists B.A., T.A, S.O., E.A.W.C., H.E., D.M.Y., R.A, R.L.W. and B.V. as inventors. The other authors declare no competing interests.

Document is current

Any future updates will be listed below